Acute lymphoblastic leukemia (ALL), a malignant disorder of lymphoid progenitor cells, is the most common hematological malignancy affects children, accounting for 25–30% of all childhood cancers with peak prevalence between the ages of 2 and 5 years [1]. The causes of pediatric acute leukemias are still not well known, the identification of causes and prevention/early intervention is clearly a worthwhile goal [2]. Previous studies have demonstrated that the interaction between genetic background, lifestyle, and these environmental factors play a critical role in the development of ALL in children [3]. MicroRNAs are a class of small (17–25 nucleotides) single-stranded noncoding RNAs that function as a sequence-targeted modifiers of gene expression through translational repression [4]. The miRNAs are important key regulators of normal hematopoiesis and their disruption could lead to leukemogenesis [5]. Mutations like single-nucleotide polymorphisms located in microRNA binding sites can cause disruption in microRNA-target interactions, leading to deregulation of the target gene expression [6]. One of these SNPs is the one found within the miR-502 binding site in the 3′-UTR of the SET8 gene. SET8 (also known as PR-SET7; located on chromosome 12q24.31) encodes a histone H4–Lys-20–specific methyltransferase which plays an important role in cell cycle–dependent transcriptional silencing and mitotic regulation [7]. There are about 129 variants of the SET8 gene
Moore, S. W. (2009). Developmental genes and cancer in children. Pediatric. Blood Cancer, 52(7), 755-760. doi:10.1002/pbc.21831. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19165888
With the development of medication, majority of childhood ALL patients could be cured. However, some of children are cured with serious adverse effects, and some children could not even be cured with current therapy. Why there is such variation among ALL patients? One possible mechanism underlying the variability in childhood ALL patients’ response to anti-leukemia medications involves gene polymorphisms. Gene polymorphisms partly accounts for the reason why childhood
MicroRNAs (miRNA) are small noncoding RNA, usually 17-25 nucleotides long that are able to bind complementary sequences of target messenger RNA (mRNA) and to induce both their degradation and translational repression (Fortunato, et al 2014). They are one of the most significant classes of non-coding RNA molecules (eg. small interfering RNA (siRNA) and ribozymes) that act within the cell. MiRNAs are also evolutionary conserved in different species from plants to humans and are encoded by their respective genes (Bader, 2012).
microRNAs (miRNAs) are a short ( about 22-26 nt length ) non coding RNA that involved in regulating gene expression at the level of post-transcription or translation and apparently control a broad range of processes of multicellular organisms including cellular differentiation, proliferation and apoptosis via targeting mRNA and cause their degradation or protein translation inhibition. miRNA transcribed from long pri-miRNA in the nucleus then processed by Dicer enzyme in the cytoplasm to form mature miRNA that incorporate in RNA induced silencing complex (RISC) to enhance their functions.
An unwanted growth of cell usually known cancer starts when cells in a part of the body begin to grow out of control and can spread to other areas of the body. There are many types of cancer out of which AML is a most commonly found cancer.
Although cancer in children is getting to the point where it is becoming rare or well it may seem that way, one in every three hundred and fifty American children will start to develop the symptoms of Acute Lymphoblastic Leukemia just by the time they would reach the age of 21 years. Even with a high percentage of being
Depletion of miR-142 in Ago2 profile, compared to total cellular profile and down regulation of miR-142 in EBV infected, was a clear indication of downregulation of miR-142 as atumor suppressor in DLBCL. It has been shown that miR-142 downregulated in many type of cancers and such low level of mir-142 represent a poor outcome . In our group, we have shown that 20% of miR142 harbor a point mutation at seed region and those point mutation results, in loss of tumor suppressor activity [41] . Here we propose
Acute myeloid leukemia (AML) is a form of cancer that begins in newly formed blood cells. This process begins in the soft, inner part of the bones called bone marrow. AML has many names, such as: acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia. The word “acute” describes the disease’s rapid progression. In most cases, this disease happens very quickly, giving the patients months to live if treatment is not started in time. The most common symptom is fatigue, but someother patients also have fever, bone pain, lethargy, shortness of breath, pale skin, frequent infections, and unusual bleeding. However, it is highly common for patients to suffer more with fatigue than any other symptom.
Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation.(1) Make sure you use the ASM system for reference citation; I do not believe this format you have is correct. The symptoms of AML are caused by the replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells.(2) These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection.(1) Several risk factors and chromosomal abnormalities have been identified. AML progresses rapidly and is typically fatal within weeks or months if left untreated. This disease is a heterogeneous clonal disorder of haemopoietic progenitor cells.(2) These cells lose the ability to differentiate normally and to respond to normal regulators of proliferation.(2) AML has a terrible prognosis, with only 23.8% of patients surviving five years after diagnosis. (3) AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. The majority of patients, despite reaching complete remission with classical chemotherapy, will relapse.(3) The persistence of malignant cells is what causes remission. (3) Acute myeloid leukemia affects both older and younger patients. However, most patients are older than 60 years old, and the prognosis is worse for
The author of this study discusses the uncommonness of adults with acute lymphocytic leukemia, and the challenges they face for treatment. Acute lymphocytic leukemia makes up only 1% of cancers found in adults, and 25% of cancers found in children. They provide detailed research and dedicated biology cytogenetics and therapies.
AML is a highly heterogeneous group of clonal disorders arising in hematopoietic progenitors. It is characterized by the proliferation of myeloid blasts showing
The human body is complex. There are many different systems and organs all working together at the same time without you even realizing. Things like cancer want to disrupt your body and how it works, but with today’s medical technology there is treatment for most cancers; leukemia in particular. “Leukemia is an abnormal rise in the number of white blood cells. The white blood cells crowd out other blood cell elements such as red blood cells and platelets. The elevated white blood cells are immature and do not function properly” (Movva). Leukemia interests me, because one day I plan on working in the medical field with children, but it has also played a major factor in my life over the past three years, continues to affect how I will live the
Acute Myeloid Leukemia is also known to be called AML and is the most common form of all acute leukemias out there. AML is generally an older person’s disease and it is uncommon in people under the age of 45 while the average age for a person with this disease is 68 years of age. AML is much more common in men than women and the risk of both male and female being diagnosed with acute myeloid leukemia is less than half of one percent. AML is rare in the diagnosis and it is estimated for the year 2018 for new patients to be diagnosed with AML is about 19,520 this is mostly in adults. The deaths that are estimated for the year 2018 is 10,670 with AML and almost all will be adults. It is said in iMedPub Journal that adults do not participate
Leukemia is the utmost common cancer in children and teens. According to statics leukemia accounts for almost 1 in 3 cancers in children. (What are the key statistics for childhood leukemia? (2015, April 17). Even so, childhood leukemia is an erratic illness. Most leukemia in children are considered acute lymphocytic leukemia (ALL). The remaining cases are considered myeloid leukemia (AML). Leukemia is a cancer that originates in early blood forming cells that are found in the bone marrow. Cells in any part of the body can become cancerous. The types of cancers that develop in children are often different then those formed in adults. A child with cancer is often the result of changes within their DNA, which occurs before birth or early
Leukemia has many different types and those types have subtypes which subdivide into more division. Leukemia is defined as an increase in cancerous white blood cells (WBC’s) which fill the bone marrow and blood stream. I will be focusing on Acute Lymphocytic Leukemia (ALL) whose mechanism I could not totally understand but will try to explain to the best of my abilities. The T lymphocyte or B lymphocyte is what becomes neoplastic in ALL. Mechanisms of leukemia include chromosome rearrangement creating a Philadelphia chromosome. The growth of the white blood cells is disrupted; hyperplasia occurs in many organs and tissues due to the lymphoblast compiling, which in turn disturb their regular function. In the bone marrow the uninhibited lymphoblast